Jun Tanaka

发表

Boosting NAD+ with a small molecule that activates NAMPT

E. Sergienko, C. Petucci, S. Gardell, 2019, Nature Communications.

Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models.

M. Yachi, J. Ohsumi, K. Araki, 2009, Journal of pharmacological sciences.

Discovery of novel pyridazine derivatives as glucose transporter type 4 (GLUT4) translocation activators.

Yoshiyuki Kobayashi, T. Tsuji, Jun Tanaka, 2019, Bioorganic & medicinal chemistry letters.

Optimization of a Urea-containing Series of Nicotinamide Phosphoribosyltransferase (NAMPT) Activators.

M. Jackson, E. Sergienko, S. Gardell, 2021, Bioorganic & medicinal chemistry letters.

Discovery of 1-[2-(1-methyl-1H-pyrazol-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl]-3-(pyridin-4-ylmethyl)urea as a potent NAMPT (nicotinamide phosphoribosyltransferase) activator with attenuated CYP inhibition.

E. Sergienko, M. Yokoyama, S. Gardell, 2021, Bioorganic & medicinal chemistry letters.

Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats.

T. Fujiwara, A. Okuno, Jun Tanaka, 2009, European journal of pharmacology.

Discovery of DS-6930, a potent selective PPARγ modulator. Part I: Lead identification.

Hideki Yamamoto, J. Ohsumi, N. Watanabe, 2018, Bioorganic & medicinal chemistry.

Discovery of DS-6930, a potent selective PPARγ modulator. Part II: Lead optimization.

Hideki Yamamoto, J. Ohsumi, N. Watanabe, 2018, Bioorganic & medicinal chemistry.

Synthesis and biological evaluation of novel (-)-Cercosporamide derivatives as potent selective PPARγ modulators.

K. Wakabayashi, Shinko Hayashi, J. Ohsumi, 2012, European journal of medicinal chemistry.

A prodrug approach towards the development of tricyclic-based FBPase inhibitors.

A. Okuno, Mizuki Takahashi, K. Tamaki, 2010, Bioorganic & medicinal chemistry letters.

Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats.

T. Fujiwara, A. Okuno, Jun Tanaka, 2009, European journal of pharmacology.

Discovery of potent and orally active tricyclic-based FBPase inhibitors.

A. Okuno, Mizuki Takahashi, T. Nishi, 2010, Bioorganic & medicinal chemistry.